SavedAdd your journal

Journals / Türk Oftalmoloji Dergisi / 2017 / Cilt: 47 - Sayı: 2

The Relationship between Serum Carbonic Anhydrase I-II Autoantibody Levels and Diabetic Retinopathy in Type 1 Diabetes Patients

Ahmet ALVER
Ahmet MENTEŞE
İrfan NUHOĞLU
Süleyman MOLLAMEHMETOĞLU
Halil İbrahim İMAMOĞLU
Cihangir EREM
Adem TÜRK
Pages
85–88
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, there was no correlation between the autoantibody levels and the presence of diabetic macular edema in caseswith DRP.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To investigate the relationship between serum carbonic anhydrase I-II (CA-I and II) autoantibody levels and diabeticretinopathy (DRP) in cases with type 1 diabetes.Materials and Methods: A total of 37 type-1 diabetic patients, 17 with DRP (group 1) and 20 without (group 2), and 38 healthycontrol subjects (group 3) were included.
📊
Key Findings & Data:Additionally, the correlation between CA-I and CA-II autoantibody levels and the presenceof diabetic macular edema was examined.Results: Mean measured CA-I autoantibody levels were 0.145±0.072, 0.117±0.047, and 0.138±0.061 ABSU in group 1, group 2, andgroup 3, respectively (p=0.327).
💡
Conclusion & Impact:However, there was no correlation between the autoantibody levels and the presence of diabetic macular edema in caseswith DRP.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To investigate the relationship between serum carbonic anhydrase I-II (CA-I and II) autoantibody levels and diabeticretinopathy (DRP) in cases with type 1 diabetes.Materials and Methods: A total of 37 type-1 diabetic patients, 17 with DRP (group 1) and 20 without (group 2), and 38 healthycontrol subjects (group 3) were included. CA-I and CA-II autoantibody levels were measured in serum samples obtained from each ofthe three groups and compared statistically. Additionally, the correlation between CA-I and CA-II autoantibody levels and the presenceof diabetic macular edema was examined.Results: Mean measured CA-I autoantibody levels were 0.145±0.072, 0.117±0.047, and 0.138±0.061 ABSU in group 1, group 2, andgroup 3, respectively (p=0.327). The average CA-II autoantibody levels achieved in the same groups were 0.253±0.174, 0.155±0.137,and 0.131±0.085 ABSU, respectively (p=0.005). No significant difference was obtained between the subgroups of group 1, with macularedema (n=8) and without (n=9), in terms of both CA-I and CA-II autoantibody levels (p=0.501, p=0.178, respectively).Conclusion: A significant correlation was observed between the development of DRP and serum CA-II autoantibody levels in type 1diabetic cases. However, there was no correlation between the autoantibody levels and the presence of diabetic macular edema in caseswith DRP.

🔖

Cite This Article

ALVER, A., MENTEŞE, A., NUHOĞLU, İ., MOLLAMEHMETOĞLU, S., İMAMOĞLU, H. İ., EREM, C., TÜRK, A. (2022). The Relationship between Serum Carbonic Anhydrase I-II Autoantibody Levels and Diabetic Retinopathy in Type 1 Diabetes Patients. Türk Oftalmoloji Dergisi, Cilt: 47 - Sayı: 2, 85–88. https://ajindex.com/articles/637822

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Adamus G, Karren L. Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy. J Autoimmun. 2009;32:133- 139. di Cesare E, Previti M, Lombardo F, Mazzù N, di Benedetto A, Cucinotta D. Prevalence of autoantibodies to carbonic anhydrase II and lactoferrin in patients with type 1 diabetes. Ann N Y Acad Sci. 2004;1037:131-132.
  2. Taniguchi T, Okazaki K, Okamoto M, Seko S, Uchida K, Seino Y. Presence of autoantibodies to carbonic anhidrase II and lactoferrin in type 1 diabetes: proposal of the concept of autoimmune exocrinopathy and endocrinopathy of the pancreas. Diabetes Care. 2001;24:1695-1696.
  3. Nishimori I, Miyaji E, Morimoto K, Kohsaki T, Okamoto N, Onishi S. Diminished cellular immune response to carbonic anhydrase II in patients with Sjögren’s syndrome and idiopathic chronic pancreatitis. JOP. 2004;5:186-192.
  4. Kiechle FL, Quattrociocchi-Longe TM, Brinton DA. Carbonic anhydrase antibody in sera from patients with endometriosis. Am J Clin Pathol. 1994;101:611-615.
  5. Kino-Ohsaki J, Nishimori I, Morita M, Okazaki K, Yamamoto Y, Onishi S, Hollingsworth M. Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjögren’s syndrome. Gastroenterology. 1996;110:1579-1586.
  6. Alver A, Menteşe A, Karahan SC, Erem C, Keha EE, Arikan MK, Eminağaoğlu MS, Deger O. Increased serum anti-carbonic anhydrase II antibodies in patients with Graves’ disease. Exp Clin Endocrinol Diabetes. 2007;115:287-291.
  7. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med. 2001;344:655-664.
  8. Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med. 2000;343:37-49.
  9. Nishi H, Tojo A, Onozato ML, Jimbo R, Nangaku M, Uozaki H, Hirano K, Isayama H, Omata M, Kaname S, Fujita T. Anti-carbonic anhydrase II antibody in autoimmune pancreatitis and tubulointerstitial nephritis. Nephrol Dial Transplant. 2007;22:1273-1275.
  10. Taniguchi T, Okazaki K, Okamoto M, Seko S, Tanaka J, Uchida K, Nagashima K, Kurose T, Yamada Y, Chiba T, Seino Y. High prevalence of autoantibodies against carbonic anhydrase II and lactoferrin in type 1 diabetes: concept of autoimmune exocrinopathy and endocrinopathy of the pancreas. Pancreas. 2003;27:26-30. Botrè F, Botrè C, Podestà E, Podda M, Invernizzi P. Effect of anticarbonic anhydrase antibodies on carbonic anhydrases I and II. Clin Chem. 2003;49:1221-1223.
  11. Turk A, Aykut M, Akyol N, Kola M, Mentese A, Sumer A, Alver A, Erdvol H. Serum anti-carbonic anhydrase antibodies and oxi